公开(公告)号：US20250059196A1

公开(公告)日：2025-02-20

申请号：US18723812

申请日：2022-12-29

Applicant: SHANGHAI HANSOH BIOMEDICAL CO., LTD. ,  JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.

Inventor： Jianrui Wu ,  Jiaqiang Dong ,  Fangfang Jin ,  Wensheng Yu ,  Lipu Zhang

IPC: C07D487/04 ,  A61K31/4155 ,  A61K31/4192 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/4725 ,  A61K31/473 ,  A61K31/4745 ,  A61K31/5025 ,  A61K31/517 ,  A61K31/519 ,  A61P35/00 ,  C07D401/12 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The invention relates to a tricyclic derivative inhibitor, a preparation method therefor, and application thereof. In particular, the present invention relates to a compound as shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, as well as a use thereof in the treatment of cancer and autoimmune diseases, wherein each substituent in general formula (I) is the same as the definition in the description.

公开(公告)号：US20250049829A1

公开(公告)日：2025-02-13

申请号：US18719989

申请日：2022-12-08

Applicant: ISTANBUL MEDIPOL UNIVERSITESI

Inventor： Ramazan KASMER ,  Metehan ILTER ,  Özge SENSOY ,  Nihal KARAKAS ,  Ozan TOPÇU

IPC: A61K31/704 ,  A61K31/196 ,  A61K31/4015 ,  A61K31/4174 ,  A61K31/4196 ,  A61K31/454 ,  A61K31/4725 ,  A61K31/506 ,  G16B15/30

Abstract: Disclosed are therapeutic molecules that can be used as an alternative to SHP2 phosphatase inhibitors, as a novel approach to targeting RAS isoforms with the G12D mutation that is involved in cancer formation.

公开(公告)号：US20250042889A1

公开(公告)日：2025-02-06

申请号：US18689379

申请日：2022-09-06

Applicant: SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. ,  QILU ANIMAL HEALTH PRODUCTS CO., LTD.

Inventor： Junfei WANG ,  Cang CHENG ,  Bo CHI ,  Daqing SUN

IPC: C07D413/14 ,  A61K31/4453 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/502 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/55 ,  A61P31/14 ,  C07D211/38 ,  C07D211/76 ,  C07D295/03 ,  C07D401/12 ,  C07D401/14 ,  C07D471/04 ,  C07D498/08

Abstract: Provided are a 3Clpro protease inhibitor, a pharmaceutical composition containing the compound of formula (I), and a method for treating coronavirus by using the compound.

公开(公告)号：US20250034116A1

公开(公告)日：2025-01-30

申请号：US18898598

申请日：2024-09-26

Applicant: BeBetter Med Inc.

Inventor： Xiong CAI ,  Yuanhui QING ,  Qijie HE ,  Yiting LIU ,  Shaobin WU ,  Yaonan HE ,  Huichen TAN ,  Yunwo WENG ,  Bin LIU ,  Mingsheng LIN ,  Xinlan DENG ,  Junling ZHU ,  Qiao FENG ,  Changgeng QIAN

IPC: C07D401/14 ,  A61K31/4155 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K38/26 ,  A61P3/04 ,  A61P3/10 ,  C07D401/08 ,  C07D401/10 ,  C07D403/10 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10

Abstract: The present invention disclosed a 1,4-diheterocyclic substituted aromatic ring or aromatic heterocyclic compound represented by formula (I). The compound can effectively inhibit the generation of 20-HETE, and has high activity, high selectivity and good pharmacokinetic characteristics. By means of the inhibition on the generation of 20-HETE, the compound can be used for treating various diseases related to 20-HETE, and thus has a great application value.

公开(公告)号：US20250011303A1

公开(公告)日：2025-01-09

申请号：US18667567

申请日：2024-05-17

Applicant: ASCLETIS BIOSCIENCE CO., LTD

Inventor： Bin Liang ,  Bailing Yang ,  Donghuang Liu ,  Jinzi Jason Wu

IPC: C07D401/14 ,  A61K31/397 ,  A61K31/4155 ,  A61K31/4725 ,  A61K31/538 ,  A61K31/5386 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D493/10 ,  C07D498/10

Abstract: The present application describes compounds of IL-17A modulator that are useful for treating an IL-17A mediated inflammatory syndrome, disorder, or disease.

公开(公告)号：US12188936B2

公开(公告)日：2025-01-07

申请号：US15734030

申请日：2019-05-30

Applicant: LUNELLA BIOTECH, INC.

Inventor： Michael P. Lisanti ,  Federica Sotgia ,  Marco Fiorillo

IPC: G01N33/574 ,  A61K31/138 ,  A61K31/404 ,  A61K31/454 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/498 ,  A61K31/519 ,  A61K31/538 ,  A61K31/65

Abstract: Cancer cells can develop resistance to endocrine therapies, such as Tamoxifen, through acquisition of the Y537S mutation. Cells transfected with the Y537S mutation showed significant increases in mitochondrial mass and membrane potential, consistent with an increase in mitochondrial biogenesis. Certain biomarkers are identified that have prognostic value of endocrine therapy resistance. The mechanism resulting in this resistance, however, leaves these treatment-resistant cells vulnerable to therapeutics that inhibit mitochondrial biogenesis. Numerous mitochondrial biogenesis inhibitors are disclosed, as well as methods for reducing or eliminating endocrine treatment resistance, improving the effectiveness of an endocrine therapy, and for treating cancer.

公开(公告)号：US20250002918A1

公开(公告)日：2025-01-02

申请号：US18703004

申请日：2022-10-22

Applicant: The Wistar Institute of Anatomy and Biology

Inventor： Dario C. Altieri

IPC: C12N15/113 ,  A61K31/12 ,  A61K31/17 ,  A61K31/282 ,  A61K31/36 ,  A61K31/437 ,  A61K31/4427 ,  A61K31/454 ,  A61K31/4725 ,  A61K31/4745 ,  A61K31/506 ,  A61K31/513 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/635 ,  A61K45/06 ,  A61P35/00 ,  G01N33/574 ,  G01N33/68

Abstract: Provided herein are methods of treating cancer in a subject in need thereof. The method includes obtaining a tumor sample from the subject and detecting an expression level(s) of one or more genes in a tumor sample. In certain embodiments, the genes comprise MMP13, XAF1, IGFBP3, MX2, IFIT1, ISG15, OAS3, CXCL10, SERPINE1, CXCL11, and CXCL3. A change in the expression level of the one or more genes as compared to a control level indicates Mic60-depleted cancer. The method further includes treating the subject for Mic60-depleted cancer.

公开(公告)号：US20240409510A1

公开(公告)日：2024-12-12

申请号：US18795654

申请日：2024-08-06

Applicant: Purdue Research Foundation

Inventor： Arun K. Ghosh ,  Ashish Sharma

IPC: C07D207/16 ,  A61K31/4025 ,  A61K31/403 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4725 ,  C07D209/52 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D417/14 ,  C07D493/04 ,  C07D493/08

Abstract: Bis-amide inhibitors of SARS-CoV-2 (COVID), compositions, and methods of treating a severe acute respiratory syndrome.

公开(公告)号：US20240398828A1

公开(公告)日：2024-12-05

申请号：US18669349

申请日：2024-05-20

Applicant: Kumquat Biosciences Inc.

Inventor： Liansheng Li ,  Xiuwen Zhu ,  Pingda Ren ,  Jonathan Deane ,  Lomon So ,  Yi Liu

IPC: A61K31/553 ,  A61K31/433 ,  A61K31/437 ,  A61K31/439 ,  A61K31/4439 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/506 ,  A61K45/06 ,  A61P37/04 ,  C07D285/06 ,  C07D417/10 ,  C07D417/14 ,  C07D471/08 ,  C07D487/10 ,  C07D491/107

Abstract: The present disclosure provides compounds and pharmaceutical compositions comprising the same. The compounds, pharmaceutical compositions thereof, and methods of using the same have a range of utilities as therapeutics, diagnostics, and research tools. The subject compositions and methods are particularly useful for potentiating immune response and/or applicable for treating cancer and other diseases.

公开(公告)号：US20240398783A1

公开(公告)日：2024-12-05

申请号：US18688859

申请日：2022-09-06

Applicant: Gismo Therapeutics, Inc.

Inventor： Paul GREGOR ,  Myung Hee KIM ,  Brian MARRON

IPC: A61K31/4709 ,  A61K31/4164 ,  A61K31/4706 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/502 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/541 ,  C07D215/42 ,  C07D233/64 ,  C07D239/94 ,  C07D401/12 ,  C07D401/14

Abstract: The disclosure provides quinoline and quinazoline derivative compounds and pharmaceutical compositions thereof. These compounds inhibit the interactions between GAG-binding amyloid peptides (GBAPs) and heparan sulfate glycosaminoglycans (HS-GAGs) and thus may be useful as therapeutics for the treatment and prevention of neurodegenerative diseases associated with amyloidosis, for example Alzheimer's Disease, and for other amyloid disorders. The present disclosure further provides methods of treatment and prevention of neurodegenerative and amyloid diseases, and methods for identifying small organic molecule compounds that can inhibit the interaction of glycosaminoglycans (GAGs) with GAG-binding amyloid peptides (GBAPs).